National Comprehensive Cancer Network

About NCCN

NCCN Flash Update: Pancreatic Adenocarcinoma

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Pancreatic Adenocarcinoma. These NCCN Guidelines® are currently available as Version 3.2017.

  • Second-line therapy for locally advanced/unresectable/metastatic disease and good performance status
    • “Pembrolizumab (Only for MSI-H or dMMR tumors)” was added as an option for both previously treated with gemcitabine-based therapy and previously treated with fluoropyrimidine-based therapy. (PANC-G 5 of 6)


  • A new footnote was added: “Consider microsatellite instability (MSI) testing and/or mismatch repair (MMR) testing on available tumor tissue (category 2B).” (PANC-6 and PANC-8)


*For your reference, the previous update (Version 2.2017) to the NCCN Guidelines for Pancreatic Adenocarcinoma, published on April 27, 2017, is available at the following link:


For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Compendium®, the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit

To view the NCCN Guidelines for Patients®, please visit

Free NCCN Guidelines apps for iPhone, iPad, and Android tablets are now available! Visit


About NCCN Flash Updates™ 
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

National Comprehensive Cancer Network® (NCCN®)
275 Commerce Drive, Suite 300
Fort Washington, PA 19034
Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

© 2017 National Comprehensive Cancer Network. All Rights Reserved.